The American College of Rheumatology released guiding principles for the allocation, use, and management of hydroxychloroquine during the COVID-19 pandemic.
An expert panel of clinicians developed guidelines for the use of rituximab in the maintenance of remission for adult ANCA-associated vasculitis.
Eric Dein, MD, discusses the pathophysiology, presentation, diagnostic approach, and symptom management of gastrointestinal dysmotility in systemic sclerosis.
Researchers described and compared triennial rates of physician recommendations for physical therapy, lifestyle counseling, and pain medication for knee osteoarthritis.
In this interview, Jane E Salmon, MD, provides insight into the risk for COVID-19 in pregnant women with rheumatic diseases.
A major adverse effect of glucocorticoid treatment is significant bone loss, which is most pronounced in the first 3 to 6 months of use.
Experts provided recommendations on contraception, assisted reproductive technologies, fertility preservation, menopausal hormone replacement therapy, pregnancy, and medication use in patients with rheumatic and musculoskeletal diseases.
Doug Roberts, MD, discusses the effect that the novel coronavirus could have in patients who are immunocompromised with rheumatic diseases.
The risk for cardiovascular disease is grossly underestimated and may account for the disproportionately high percentage of cardiovascular-related deaths in this population.
The Osteogenesis Imperfecta and Childhood Osteoporosis Working Group of the Spanish Society of Pediatric Rheumatology developed guidelines for the prevention, diagnosis, and treatment of secondary childhood osteoporosis.